DK2185586T3 - Immunmodulation via c-type-lectin - Google Patents

Immunmodulation via c-type-lectin Download PDF

Info

Publication number
DK2185586T3
DK2185586T3 DK08776024.5T DK08776024T DK2185586T3 DK 2185586 T3 DK2185586 T3 DK 2185586T3 DK 08776024 T DK08776024 T DK 08776024T DK 2185586 T3 DK2185586 T3 DK 2185586T3
Authority
DK
Denmark
Prior art keywords
cells
clec9a
antigen
cell
response
Prior art date
Application number
DK08776024.5T
Other languages
English (en)
Inventor
David Sancho-Madrid
Oliver Schulz
Neil Charles Rogers
E Sousa Caetano Reis
Daniel Pennington
Olivier Pierre Joffre
Original Assignee
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Rec Tech Ltd filed Critical Cancer Rec Tech Ltd
Application granted granted Critical
Publication of DK2185586T3 publication Critical patent/DK2185586T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)

Claims (24)

1. Sammensætning omfattende et peptidantigen, hvor antigenet er kovalent koblet til et antistof med affinitet for CLEC9a eller et funktionelt fragment deraf med affinitet for CLEC9a, og hvor sammensætningen eventuelt yderligere omfatter en farmaceutisk acceptabel bærer.
2. Sammensætning ifølge krav 1, hvor antigenet og antistoffet eller det funktionelle fragment deraf er del af den samme peptidkæde.
3. Sammensætning ifølge krav 1 eller krav 2, hvor antistoffet eller det funktionelle fragment deraf er en agonist af CLEC9a.
4. Sammensætning ifølge et hvilket som helst af kravene 1 til 3, hvor antigenet er eller omfatter et peptid fra et protein udtrykt ved et patogen eller en parasit, såsom et viralt protein, eller et protein fra en cancercelle, såsom et tumorspecifikt antigen.
5. Sammensætning ifølge et hvilket som helst af kravene 1 til 4, formuleret til intravenøs, intramuskulær, intraperitoneal, nasal, subkutan eller intradermal indgivelse.
6. Sammensætning ifølge et hvilket som helst af kravene 1 til 5, til anvendelse i en fremgangsmåde til medicinsk behandling, f.eks. til anvendelse ved stimulering af et immunrespons mod antigenet eller til anvendelse ved induktion af tolerance over for antigenet.
7. Sammensætning til anvendelse ifølge krav 6, hvor det immunrespons, der skal stimuleres, er et CTL-respons, Th1 -respons, Th2-respons, Th17-respons eller et Treg-respons.
8. Sammensætning til anvendelse ifølge krav 6 eller krav 7, hvor sammensætningen indgives, eller er formuleret til indgivelse med, en adjuvans, f.eks. retinsyre, en CD40-agonist eller en TLR-agonist, IL-1 eller TNF-alpha.
9. Sammensætning til anvendelse ifølge krav 7, hvor responset er et Treg-respons, og hvor antigenet er et, som det er ønskeligt at inhibere eller undertrykke et uønsket immunrespons mod.
10. Anvendelse af en sammensætning ifølge et hvilket som helst af kravene 1 til 5 i fremstillingen af et medikament til stimulering af et immunrespons mod antigenet eller til anvendelse ved induktion af tolerance over for antigenet.
11. Anvendelse ifølge krav 10, hvor det immunrespons, der skal stimuleres, er et CTL-respons, Th1-respons, Th2-respons, Th17-respons eller et Treg-respons.
12. Anvendelse ifølge krav 10 eller krav 11, hvor sammensætningen indgives, eller er formuleret til indgivelse med, en adjuvans, f.eks. retinsyre, en CD40-agonist eller en TLR-agonist, IL-1 eller TNF-alpha.
13. Anvendelse ifølge krav 11, hvor responset er et Treg-respons, og hvor antigenet er et, som det er ønskeligt at inhibere eller undertrykke et uønsket immunrespons mod.
14. Fremgangsmåde til målretning af et peptidantigen mod en antigenpræsenterende celle, omfattende at bringe den antigenpræsenterende celle in vitro i kontakt med en sammensætning ifølge et hvilket som helst af kravene 1 til 4, og hvor den antigenpræsenterende celle udtrykker CLEC9a.
15. Fremgangsmåde ifølge krav 14, hvor den antigenpræsenterende celle er en dendritisk celle, eventuelt hvor den dendritiske celle kan krydspræsentere ekstracellulært antigen via MHC klasse l-molekyler.
16. Nukleinsyre, der kan hybridisere til mRNA eller DNA kodende CLEC9a, og som er antisense-RNA eller DNA, siRNA eller et ribozym, eller et antistof med affinitet for CLEC9a eller et funktionelt fragment deraf med affinitet for CLEC9a og som omfatter et toksinmolekyle, der kan dræbe en celle, eller et enzym, der kan omdanne et ikke-toksisk molekyle til et toksisk molekyle, til anvendelse i en fremgangsmåde til medicinsk behandling, f.eks. til anvendelse ved inhibering af et immunrespons.
17. Nukleinsyre, eller antistof eller funktionelt fragment, til anvendelse ifølge krav 16, hvor det immunrespons, der skal inhiberes, er en inflammatorisk eller autoimmun tilstand.
18. Nukleinsyre, eller antistof eller funktionelt fragment, til anvendelse ifølge krav 17, hvor tilstanden er: - rheumatoid arthritis, systemisk lupus erythematosus, sklerodermi, Sjogrens syndrom, autoimmun diabetes (især type I), thyroiditis eller psoriasis; - multipel sklerose eller myasthenia gravis; - Crohns sygdom, kolitis, cøliaki eller hepatitis; - aterosklerose, kardiomyopati, gigtfeber, endocarditis eller vaskulitis; - emfysem, luftvejsinfektion; - allergiske processer, overfølsomhedsreaktion (type I, II, III eller IV), astma eller rhinitis; - transplantat- eller graftafstødning, eller graft-versus-host-reaktion; eller - septisk shock-syndrom.
19. Anvendelse af (i) en nukleinsyre, der kan hybridisere til mRNA eller DNA kodende CLEC9a, og som er antisense-RNA eller DNA, siRNA eller et ri-bozym, eller (ii) et antistof med affinitet for CLEC9a eller et funktionelt fragment deraf med affinitet for CLEC9a, som omfatter et toksinmolekyle, der kan dræbe en celle, eller et enzym, der kan omdanne et ikke-toksisk molekyle til et toksisk molekyle, ved fremstilling af et medikament til inhibering af et immunrespons.
20. Anvendelse ifølge krav 19, hvor det immunrespons, der skal inhiberes, er en inflammatorisk eller autoimmun tilstand.
21. Anvendelse ifølge krav 20, hvor tilstanden er: - rheumatoid arthritis, systemisk lupus erythematosus, sklerodermi, Sjogrens syndrom, autoimmun diabetes (især type I), thyroiditis eller psoriasis; - multipel sklerose eller myasthenia gravis; - Crohns sygdom, kolitis, cøliaki eller hepatitis; - aterosklerose, kardiomyopati, gigtfeber, endocarditis eller vaskulitis; - emfysem, luftvejsinfektion; - allergiske processer, overfølsomhedsreaktion (type I, II, III eller IV), astma eller rhinitis; - transplantat- eller graftafstødning, eller graft-versus-host-reaktion; eller - septisk shock-syndrom.
22. Fremgangsmåde til isolering af en antigenpræsenterende celle fra en prøve, omfattende at bringe prøven i kontakt med et antistof med affinitet for CLEC9a eller et funktionelt fragment deraf med affinitet for CLEC9a og at isolere en eller flere celler, hvortil bindemidlet er bundet, hvor den antigenpræsenterende celle eventuelt er en dendritisk celle, og endnu yderligere eventuelt kan krydspræsentere ekstracellulært antigen via MHC klasse I-molekyler.
23. Fremgangsmåde til stimulering af et immunrespons imod et peptidantigen omfattende at isolere en antigenpræsenterende celle eller population deraf ved hjælp af en fremgangsmåde ifølge krav 22 og at bringe cellen eller populationen af celler in vitro i kontakt med antigenet og eventuelt en ad-juvans.
24. Fremgangsmåde ifølge krav 23 omfattende, efter trinnet med at bringe i kontakt, at bringe de antigenpræsenterende celler in vitro i kontakt med en population af autologe celler omfattende en eller flere T-celler, og eventuelt at ekspandere T-cellerne i populationen.
DK08776024.5T 2007-07-20 2008-07-21 Immunmodulation via c-type-lectin DK2185586T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92999907P 2007-07-20 2007-07-20
GBGB0805159.1A GB0805159D0 (en) 2008-03-19 2008-03-19 Immune modulation via C-type lectin
PCT/GB2008/002504 WO2009013484A1 (en) 2007-07-20 2008-07-21 Immune modulation via c-type lectin

Publications (1)

Publication Number Publication Date
DK2185586T3 true DK2185586T3 (da) 2016-01-18

Family

ID=39356783

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08776024.5T DK2185586T3 (da) 2007-07-20 2008-07-21 Immunmodulation via c-type-lectin

Country Status (13)

Country Link
US (2) US8580266B2 (da)
EP (1) EP2185586B1 (da)
JP (1) JP5577246B2 (da)
CN (1) CN101896500B (da)
AU (1) AU2008278831B2 (da)
CA (1) CA2693277A1 (da)
DK (1) DK2185586T3 (da)
ES (1) ES2557935T3 (da)
GB (1) GB0805159D0 (da)
HR (1) HRP20160033T1 (da)
HU (1) HUE026387T2 (da)
SI (1) SI2185586T1 (da)
WO (1) WO2009013484A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009026660A1 (en) 2007-08-30 2009-03-05 Walter And Eliza Hall Institute Of Medical Research Dendritic cell marker and uses thereof
JP2011519959A (ja) * 2008-05-13 2011-07-14 ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ 破壊された細胞膜を有する細胞、病原体に感染した細胞、死にかけている細胞または死細胞を検出する方法
WO2010108215A1 (en) * 2009-03-23 2010-09-30 The Walter And Eliza Hall Institute Of Medical Research Compounds and methods for modulating an immune response
GB201006768D0 (en) 2010-04-22 2010-06-09 Cancer Rec Tech Ltd Method for obtaining dendritic cells
JP2013525496A (ja) * 2010-05-07 2013-06-20 ベイラー リサーチ インスティテュート ヒトｃｄ８＋ｔ細胞の樹状細胞免疫受容体（ｄｃｉｒ）媒介クロスプライミング
WO2013088136A1 (en) 2011-12-12 2013-06-20 Ahrens Susan Ligand for dngr-1 receptor
AU2013323538B2 (en) * 2012-09-26 2019-07-11 Cook Biotech Incorporated Medical device design, manufacture and testing systems
US20160015803A1 (en) * 2014-07-18 2016-01-21 Ross Kedl Immunostimulatory combinations and use thereof
CA2950501C (en) * 2014-07-21 2022-08-09 Nestec S.A. Nutritional products to promote safe swallowing for individuals with dysphagia
CN104789689B (zh) * 2015-05-13 2018-10-02 北京泱深生物信息技术有限公司 作为肺腺癌诊治靶标的clec9a基因
CA2994965A1 (en) * 2015-08-06 2017-02-09 Memorial Sloan-Kettering Cancer Center Methods and compositions for tumor therapy
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
CN109071632B (zh) * 2016-02-05 2022-12-30 奥里尼斯生物科学私人有限公司 靶向性治疗剂及其用途
CN105924501B (zh) * 2016-04-28 2019-04-02 郑州大学 靶向Clec9a的亲和肽WH肽
WO2018035364A1 (en) * 2016-08-17 2018-02-22 The Broad Institute Inc. Product and methods useful for modulating and evaluating immune responses
BR112020002706A2 (pt) * 2017-08-09 2020-08-25 Orionis Biosciences Inc. agentes de ligação a clec9a e uso dos mesmos
US11498966B2 (en) 2017-08-09 2022-11-15 Orionis Biosciences Inc. PD-1 and PD-L1 binding agents
EP3665201A4 (en) 2017-08-09 2021-06-02 Orionis Biosciences, Inc. CD8 BINDERS
JPWO2019244973A1 (ja) * 2018-06-20 2021-07-08 中外製薬株式会社 標的細胞に対する免疫反応を活性化する方法およびその組成物
EP3841112A1 (en) 2018-08-24 2021-06-30 Codiak BioSciences, Inc. Extracellular vesicles targeting dendritic cells and uses thereof
US20220331349A1 (en) * 2019-01-08 2022-10-20 University Of Georgia Research Foundation, Inc. Targeted nanoparticles and their uses related to fungal infections
WO2020179700A1 (ja) * 2019-03-01 2020-09-10 国立大学法人筑波大学 アレルギー疾患を処置することに用いるための組成物
CN111544592B (zh) * 2020-03-13 2022-05-03 中山大学附属第一医院 模式识别受体Dectin-1抑制剂对受体移植物的免疫保护及诱导免疫耐受的应用
EP3892739A1 (en) * 2020-04-09 2021-10-13 Centre Léon Bérard Type iii interferon for use as a biomarker to predict response to a cancer treatment
GB202011859D0 (en) 2020-07-30 2020-09-16 Francis Crick Institute Ltd Cytosolic delivery
WO2023203198A1 (en) 2022-04-21 2023-10-26 The Francis Crick Institute Limited Bispecific binding agent
WO2024018062A1 (en) 2022-07-21 2024-01-25 The Francis Crick Institute Limited Immunoconjugate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020090672A1 (en) * 2000-01-31 2002-07-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
WO2001055309A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
DE10142994A1 (de) * 2001-09-01 2003-03-27 Keiper Gmbh & Co Längseinsteller für einen Fahrzeugsitz
CA2469941A1 (en) * 2001-12-10 2003-07-03 Nuvelo, Inc. Novel nucleic acids and polypeptides

Also Published As

Publication number Publication date
GB0805159D0 (en) 2008-04-23
CN101896500A (zh) 2010-11-24
AU2008278831B2 (en) 2013-11-21
CN101896500B (zh) 2015-09-30
US8580266B2 (en) 2013-11-12
ES2557935T3 (es) 2016-01-29
EP2185586A1 (en) 2010-05-19
WO2009013484A1 (en) 2009-01-29
HRP20160033T1 (hr) 2016-02-26
AU2008278831A1 (en) 2009-01-29
JP5577246B2 (ja) 2014-08-20
JP2010534200A (ja) 2010-11-04
CA2693277A1 (en) 2009-01-29
HUE026387T2 (en) 2016-05-30
SI2185586T1 (sl) 2016-02-29
US9205153B2 (en) 2015-12-08
US20100221265A1 (en) 2010-09-02
US20140328865A1 (en) 2014-11-06
EP2185586B1 (en) 2015-10-14

Similar Documents

Publication Publication Date Title
DK2185586T3 (da) Immunmodulation via c-type-lectin
US11306134B2 (en) Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof
US11026973B2 (en) Engineered phagocytic receptor compositions and methods of use thereof
KR102647696B1 (ko) Mage-a4 유래 펩티드를 인식하는 항원 결합성 단백질
Sancho et al. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin
CA2942459C (en) Claudin-6-specific immunoreceptors and t cell epitopes
KR20170140266A (ko) 클라우딘-18.2-특이적 면역수용체 및 t 세포 에피토프
TW201841937A (zh) 用於白血病和其他癌症免疫治療的新穎肽和肽組合物
US10849965B2 (en) H3.3 CTL peptides and uses thereof
CN110637028A (zh) Hla限制性vcx/y肽和t细胞受体及其用途
WO2023119295A1 (en) Lilrb polypeptides and uses thereof
JP2023527067A (ja) 免疫調節複合体および治療のためのその使用
Spadafora Immunogenic properties of differentially activated Dendritic Cells
KR20230147078A (ko) 치료에 사용하기 위한 t 세포
King Developing DNA fusion gene vaccines: from pre-clinical models to clinical studies